Skip to content

Application of ABCD regimen in induction chemotherapy for newly diagnosed multiple myeloma

Application of ABCD regimen in induction chemotherapy for newly diagnosed multiple myeloma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019859
Enrollment
Unknown
Registered
2018-12-02
Start date
2018-11-29
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

ABCD group:ABCD Chemotherapy

Sponsors

Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) After hematuria immunofixation electrophoresis, bone marrow examination and cytogenetics, CRAB symptoms, SLiM symptoms, diagnosis of active multiple myeloma under the IMWG standard (symptomatic myeloma); 2) The ECOG score is 0 to 3; 3) Liver function is sound (BUN = 1.5 times the reference value, SGPT = 2 times the reference value); 4) Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraceptive measures during treatment; Subjects must sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Has been diagnosed with other diseases of the blood system; 2) Those who have participated in other clinical trials within 30 days; 3) pregnant and breast-feeding patients; 4) Have received any treatment for this tumor in the past 3 years, but remove superficial bladder cancer, basal cells or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia (CIN) or prostate intraepithelial neoplasia (PIN); 5) Active viral or bacterial infections that are not controlled by appropriate anti-infective treatment; 6) The serological response of HIV or active hepatitis C virus is known to be positive; 7) suffering from a mental illness or other condition that does not meet the requirements of research treatment and monitoring; 8) bone marrow evacuation; 9) Those who are known to be allergic to any of the ingredients in the protocol; 10) Have received bortezomib or have received a hematopoietic stem cell transplant in the past year.

Design outcomes

Primary

MeasureTime frame
VGPR;OS;PFS;

Countries

China

Contacts

Public ContactXie Yanhui

Huadong Hospital

yanhuixie@163.com+86 13321957387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026